In Vivo Assay Quality Control Service
Choosing Creative Biolabs ensures a seamless transition from discovery to submission by implementing a robust quality control (QC) framework and standardized protocols. We de-risk development by addressing biological complexities, high inter-subject variability, and "false-positive" signals through optimal model selection. Our platform provides high-fidelity tumor microenvironment (TME) characterization and therapeutic analyte validation. Whether developing CAR-T, TCR-T, or gene-editing therapies, we provide the surgical precision required to validate potency and safety profiles, ensuring results are biologically relevant.
Introduction of Quality Control for In Vivo Assays
In vivo quality control is the cornerstone of successful therapeutic translation. It represents a systematic commitment to verifying that every experimental variable is controlled, monitored, and analyzed with absolute scientific integrity. In the context of modern immunotherapy, where complex cellular products interact with dynamic biological systems, QC mitigates the risks of heterogeneity and physiological noise. By integrating advanced imaging, molecular profiling, and standardized methodologies, Creative Biolabs ensures that your preclinical data serves as a reliable foundation for future development.
Comprehensive Solutions for In Vivo Success
Rigorous Therapeutic Release Testing
We execute stringent pre-administration checks on all cellular and molecular products. By verifying viability, purity, and expression stability, we ensure your in vivo outcomes are driven by therapeutic design, not contaminants.
High-Fidelity Model Validation
Our specialists perform deep genetic and immunological profiling of every animal model. This baseline QC guarantees that the physiological environment accurately recapitulates human disease kinetics for reliable translational insights.
Advanced Longitudinal Monitoring
Utilizing non-invasive bioluminescence and molecular tracking, we provide a dynamic view of therapeutic efficacy. This allows for real-time adjustments and the capture of critical data points throughout the study.
Audit-Ready Statistical Verification
Every dataset undergoes a multi-layered statistical audit to eliminate bias. We provide transparent, reproducible evidence of therapeutic potency, ensuring your preclinical package meets the highest international regulatory standards.
Accelerate Your Drug Development Strategy — Request a Technical Consultation with Our Experts Today
Workflow
A detailed, systematic approach is essential for ensuring every in vivo study produces reliable and actionable insights. Creative Biolabs utilizes a structured methodology to eliminate technical bias and maximize data integrity.
Publication
This study presents a novel mesothelin-based CAR-T cell therapy targeting MUC16/CA125 in ovarian cancer. MSLN-CAR T cells demonstrated potent, MUC16-dependent cytotoxicity against ovarian cancer cells and cancer stem-like cells in vitro. In a xenograft mouse model, both systemic and intraperitoneal administration suppressed tumor growth, with peritoneal delivery inducing sustained remission. These findings highlight MSLN-CAR T cells as a promising immunotherapeutic strategy for MUC16-positive ovarian cancer.
Fig.1 Efficacy of MSLN-targeting CAR T cells against ovarian cancer xenografts. 1
Why Choose Us
Creative Biolabs distinguishes itself through a unique synergy of decades of biological expertise and cutting-edge analytical platforms. Unlike traditional CROs, we integrate patient-derived organoids (PDOs) and published data benchmarks into our QC framework to provide a more accurate prediction of human clinical response. Our unique selling proposition lies in our ability to monitor the "unseen" variables. By utilizing advanced genomic profiling and real-time imaging, we identify mechanisms of resistance, such as antigen escape or T-cell exhaustion, early in the preclinical phase. This transparency allows our clients to pivot or optimize their constructs before committing to the massive expenditures of early-stage trials.
Partner with a Global Leader in Preclinical Excellence — Discover the Creative Biolabs Advantage Today
FAQs
How does Creative Biolabs handle high variability in animal models?
We implement strict baseline characterization and randomized allocation to ensure that biological noise is minimized and therapeutic signals are clearly isolated.
Can your QC services support multi-site global programs?
Yes, we offer specialized cross-validation and method transfer verification to ensure data consistency across different laboratory environments.
What technologies are used for longitudinal tumor monitoring?
We primarily utilize bioluminescence imaging (BLI) for luciferase-tagged models and high-resolution flow cytometry for liquid tumor monitoring.
Customer Review
-
Precision Data Integrity
Utilizing Creative Biolabs' quality control for in vivo assays facilitated a breakthrough in our solid tumor program. Their ability to correlate cell exhaustion markers with in vivo persistence gave us the clarity we needed to move forward. - Dr. Aex L -
Unrivaled Model Expertise
The transition to immune-competent models was seamless thanks to Creative Biolabs. Their baseline QC of the host immune system ensured that our combination therapy results were both accurate and reproducible. - Prof. Sra K
Related Services
Immuno-Oncology Animal Models
Creative Biolabs provides a vast immuno-oncology animal model platform, featuring humanized and syngeneic models for CAR-T and checkpoint inhibitor validation. We deliver customized preclinical solutions to optimize drug discovery and model selection.
Learn More →Contrast-Enhanced CT Tumor Imaging Service
Creative Biolabs provides CE-CT and DCE-CT services, delivering high-resolution 3D tumor imaging. We optimize radiation parameters and quality control to identify biomarkers and evaluate therapeutic responses during early-phase drug discovery.
Learn More →Contact Us
Creative Biolabs offers an industry-leading QC framework for in vivo assays, bridging the gap between discovery and the clinic with GLP-compliant data, advanced imaging, and expert scientific analysis. For more information or to discuss your specific project needs, please reach out to our specialist team.
Ready to Elevate Your Research? Contact Our Team for More Information and to Discuss Your Project Goals Today
Reference
- Guo, Jing, et al. "Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer." Journal of translational medicine 22.1 (2024): 367. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12967-024-05174-y
Download our brochure